Revised FIGO Staging System

Hee Sug Ryu

doi:10.5124/jkma.2010.53.3.245

Journal List > J Korean Med Assoc > v.53(3) > 1042254

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ryu: Revised FIGO Staging System

Continuing Education Column

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2010; 53(3): 245-249.

Published online: 31 March 2010

DOI: https://doi.org/10.5124/jkma.2010.53.3.245

Revised FIGO Staging System

Hee Sug Ryu, MD

Department of Obstetrics and Gynecology, Ajou University School of Medicine, Korea. hsryu@ajou.ac.kr

Abstract

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging system for carcinoma of the vulva, cervix, and endometrium in 2009. A new staging system for uterine sarcoma has been designed. This review summarizes the changes. There were minor changes in carcinoma of endometrium and cervix. The staging systems for uterine sarcomas were newly developed. Major changes were made for the carcinoma of vulva. There were no changes for cancer of the ovary, tube, vagina, and gestational trophoblastic neoplasia.

Keywords: FIGO staging, Gynecologic cancer

Figures and Tables

Table 1

Carcinoma of endometrium

^*Either G1, G2, G3.

^**Endocervical glandular involvement only should be consid-ered as Stage I and no longer as Stage II.

^#Positive cytology has to be reported separately without changing the stage.

Table 2

Carcinoma of the cervix uteri

^*All macroscopically visible lesions-even with superhicial invasion-are allotted to stage IB carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.00 mm and a horizontal extension of not >7.00 mm. Depth of invasion should not be >5.00 mm taken from the base of the epithelium of the original tissue-superficial or glandular. The depth of invasion should always be reported in mm, even in those cases with "early (minimal) stromal invasion" (~1 mm).

^**On rectal examination, there is no cancer-free space between the tumor and the pelvic wall. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due another cause.

Table 3

Carcinoma of the vulva

^*The depth of invasion is definde as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.

Table 4

Staging for uterine sarcomas (leiomyosarcomas, endometrial stromal sarcomas, adenosarcomas, and carcionsarcomas)

^*Note: Simultaneous tumors of the uterine corpus and ovary/pelvis in association with ovarian/pelvic endometriosis should be classified as independent primary tumors.

References

1. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009. 105:103–104.

2. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009. 105:109.

3. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009. 105:107–108.

4. Burghardt E, Ostor A, Fox H. The new FIGO definition of cervical cancer stage IA: a critique. Gynecol Oncol. 1997. 65:1–5.

5. Cheng X, Cai S, Li Z, Tang M, Xue M, Zang R. The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. World J Surg Oncol. 2004. 2:47.

6. Hricak H, Gatsonis C, Coakley FV, Snyder B, Reinhold C, Schwartz LH, Woodward PJ, Pannu HK, Amendola M, Mitchell DG. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation-ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology. 2007. 245:491–498.

7. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Lee CC, Tang SG, Hsueh S. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005. 63:492–499.

8. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007. 107:310–315.

9. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1991. 164:997–1003. discussion 1003-1004.

10. Tantipalakorn C, Robertson G, Marsden DE, Gebski V, Hacker NF. Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstet Gynecol. 2009. 113:895–901.

11. Hacker NF. Revised FIGO staging for carcinoma of the vulva. Int J Gynaecol Obstet. 2009. 105:105–106.

12. Fons G, Hyde SE, Buist MR, Schilthuis MS, Grant P, Burger MP, van der Velden J. Prognostic value of bilateral positive nodes in squamous cell cancer of the vulva. Int J Gynecol Cancer. 2009. 19:1276–1280.

13. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009. 104:177–178.

TOOLS

Similar articles